

The effect of clodronate on the incidence of hip fracture and consequences for health and costs

Submission date 25/10/2000	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 25/10/2000	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 12/09/2007	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr EV McCloskey

Contact details

Department of Human Metabolism & Clinical Biochemistry
University of Sheffield Medical School
Beech Hill Road
Sheffield
United Kingdom
S10 2RX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

G9518113

Study information

Scientific Title

Study objectives

To determine in an elderly female population who would best benefit from an intervention aimed at reducing the incidence of hip fracture

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Orthopaedics, rheumatology

Interventions

Clodronate/control

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Fragility fractures, particularly hip fracture

Secondary outcome measures

Not provided at time of registration

Overall study start date

10/06/1996

Completion date

01/12/2002

Eligibility

Key inclusion criteria

Women aged 75 years or older willing to participate

Participant type(s)

Patient

Age group

Senior

Sex

Female

Target number of participants

5700

Key exclusion criteria

Drugs and diseases likely to impair the efficacy of intervention or the interpretation of results

Date of first enrolment

10/06/1996

Date of final enrolment

01/12/2002

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Department of Human Metabolism & Clinical Biochemistry

Sheffield

United Kingdom

S10 2RX

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/01/2007		Yes	No